Navigation Links
Bionovo Announces Second Quarter 2009 Highlights and Financial Results
Date:8/10/2009

y and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Financial Tables on Following Pages


                                    Bionovo, Inc.
                            (A Development Stage Company)
                        Consolidated Statements of Operations
                 (Unaudited, in thousands, except per share amounts)

                                                                 Accumulated
                                                              from February 1,
                                                               2002 (Date of
                         Three months ended    Six months ended  inception) to
                                June 30,             June 30,      June 30,
                         ------------------     ---------------- ------------
                             2009      2008      2009      2008      2009
                             ----      ----      ----      ----      ----

    Revenues                   $7        $-        $7        $-      $899

    Operating expenses:
      Research and
'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 ... has been commenced in the United States District Court ... on behalf of investors who purchased Galectin Therapeutics Inc. ... 6, 2014 and July 28, 2014. For ... The complaint alleges that during the Class Period the ...
(Date:8/28/2014)...   Edison Nation Medical , the premier ... for product ideas to improve the health and ... through the 6-month search ( www.EdisonNationMedical.com/Seniors ) will ... healthcare retailers with whom Edison Nation Medical has ... 65 and older. The objective of ...
(Date:8/28/2014)...  Seres Health, a clinical-stage therapeutics company developing ... microbiome, announced today that Dr. David Cook ... Chief Scientific Officer, will be presenting at the ... (ICAAC). The presentation will highlight the scientific and ... bacterial spores derived from the human microbiome, and ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2
... CRAIGAVON, Northern Ireland , August 2, 2010 ... a range of solutions,specifically designed to meet the needs of the ... , ... biopharma companies in adopting,biomarker strategies to enable them to better understand ...
... Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that ... Healthcare Conference on Thursday, August 5, 2010 at 1:15 ... held at the Sheraton New York Hotel & Towers.  Steve Worland, Ph.D., ... Anadys and its clinical development programs. , ...
Cached Medicine Technology:Almac Launch Biomarkers for Biopharma 2Almac Launch Biomarkers for Biopharma 3Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference 2
(Date:8/28/2014)... Governor of Yucatán, Rolando Zapata Bello, presented the ... event is organized by the Microcredit Summit Campaign in ... Microenterprise Financing Program ( PRONAFIM ) and will take ... Convention Center Yucatan Siglo XXI in the city of ... to host the 17th Microcredit Summit logistically but especially ...
(Date:8/28/2014)... August 28, 2014 Bank lending to the ... year, down by 0.13% in real terms, and continuing to ... new study by UHY, the international accountancy network. , UHY ... businesses in particular, the credit crunch lingers on. , UHY ... the last year have been wiped out by inflation. Over ...
(Date:8/28/2014)... fall from trees and learn to flap their forelimbs to ... pump their "arms" to get aloft? , The answer is ... University of California, Berkeley, study provides a new piece of ... midair, a talent that could have helped their ancestors learn ... study looked at how baby birds, in this case chukar ...
(Date:8/28/2014)... Albert Einstein College of Medicine of Yeshiva University ... Sudan ebolavirus (SUDV), one of the two most lethal strains ... now devastating West Africa. First identified in 1976, SUDV has ... that have killed more than 400 people in total. The ... , Between 30 and 90 percent of people infected with ...
(Date:8/28/2014)... herbal medication practitioner in Melbourne for back pain ... of intensive care and emergency physicians to call ... complementary medications. , Writing in Emergency Medicine ... for Emergency Medicine, emergency medicine trainees Dr Angelly ... Care Unit at the Royal Melbourne Hospital and ...
Breaking Medicine News(10 mins):Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:Drug shows promise against Sudan strain of Ebola in mice 2Health News:Deadly remedy: Warning issued about Chinese herbal medicine 2
... Annual JMP Securities Research Conference ... on May 21 - ... Meeting on May 22 -, SAN DIEGO, May 14 Ardea Biosciences, Inc.,(Nasdaq: ... Annual Research Conference. Additionally, Ardea will be,hosting a live webcast and conference call of ...
... 14 Biotel Inc. (OTC Bulletin,Board: BTEL) announced results ... earnings of $99,000, or $0.03 per diluted share, on ... or $0.07 per diluted,share, on revenues of $2,990,000 for ... ended March 31, 2008, Biotel had net earnings of ...
... Patients more likely to survive using chemoradiation, and new ... -- Tonsil and tongue cancers linked to human papillomavirus ... treatments, while those that express high levels of a ... most deadly, a new study concludes. , University of ...
... other treatments work well, too, giving patients options , , WEDNESDAY, ... kind supports the use of a popular three-drug regimen for ... drugs is a good alternative. , But an older ... Sharon Riddler, assistant professor of medicine at the University of ...
... , , WEDNESDAY, May 14 (HealthDay News) -- A bundle of ... cardiovascular disease in a study of older Swedish men, researchers ... long process that might one day lead to widespread medical ... such as high blood pressure and cholesterol, said Dr. Johan ...
... Honored for Their Research -, PALO ALTO, ... Ph.D. students and two professors with the company,s ... field of organic,chemistry. The winners participated in Roche,s ... on the important role of organic,chemistry in pharmaceutical ...
Cached Medicine News:Health News:Ardea Biosciences Announces Upcoming Corporate Meetings 2Health News:Ardea Biosciences Announces Upcoming Corporate Meetings 3Health News:Biotel Announces Profitable Third Quarter Ended March 31, 2008 2Health News:HPV Tied to Better Tongue, Tonsil Cancer Outcomes 2Health News:Study Supports Popular HIV Drug Regimen 2Health News:Study Supports Popular HIV Drug Regimen 3Health News:Biomarkers Predict Heart Deaths 2Health News:Biomarkers Predict Heart Deaths 3Health News:Roche Symposium Showcases Accomplishments of Next Generation of Chemists 2Health News:Roche Symposium Showcases Accomplishments of Next Generation of Chemists 3
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Medicine Products: